Evaluation of microRNA-10b prognostic significance in a prospective cohort of breast cancer patients

Paola Parrella, Raffaela Barbano, Barbara Pasculli, Andrea Fontana, Massimiliano Copetti, Vanna M. Valori, Maria L. Poeta, Giuseppe Perrone, Daniela Righi, Marina Castelvetere, Michelina Coco, Teresa Balsamo, Maria Morritti, Fabio Pellegrini, Andrea Onetti-Muda, Evaristo Maiello, Roberto Murgo, Vito M. Fazio

Research output: Contribution to journalArticle

Abstract

Background: MicroRNA-10b (miR-10b) has a prominent role in regulating tumor invasion and metastasis by targeting the HOXD10 transcriptional repressor and has been found up-regulated in several tumor types. Methods: We evaluated the expression of miR-10b in paired tumor and normal specimens obtained from a prospective cohort of breast cancer patients with at least 36 months follow-up enrolled according to the REMARK guidelines (n = 150). RNA quality was measured and only samples with RNA Integrity Number (RIN) ≥7.0 were analyzed. Results: The relative expression of miR-10b in tumor as compared to its normal counterpart (RER) was determined by RT-qPCR. miR-10b RERs were higher in the subgroup of patients with synchronous metastases (n = 11, Median 0.25; IQR 0.11-1.02) as compared with patients without metastases (n = 90, Median 0.09; IQR 0.04-0.29) (p = 0.028). In the subgroup of patients without synchronous metastases (n = 90), higher miR-10b RERs were associated with increased risk of disease progression and death in both univariable (HR 1.16, p = 0.021 and HR 1.20, p = 0.015 respectively for 0.10 unitary increase of miR-10b RERs levels) and multivariable (HR1.30, p <0.001, and HR 1.31, p = 0.003 respectively for 0.10 unitary increase of miR-10b RERs levels) Cox regression models. The addition of miR-10b RERs to the Nottingham Prognostic Index (NPI) provided an improvement in discrimination power and risk reclassification abilities for the clinical outcomes at 36 months. Survival C-indices significantly increased from 0.849 to 0.889 (p = 0.009) for OS and from 0.735 to 0.767 (p = 0.050) for DFS. Conclusions: Our results provide evidences that the addition of miR-10b RERs to the prognostic factors used in clinical routine could improve the prediction abilities for both overall mortality and disease progression in breast cancer patients.

Original languageEnglish
Article number142
JournalMolecular Cancer
Volume13
Issue number1
DOIs
Publication statusPublished - Jun 4 2014

Keywords

  • Breast cancer
  • Metastasis
  • microRNA
  • RT-qPCR

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Oncology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Evaluation of microRNA-10b prognostic significance in a prospective cohort of breast cancer patients'. Together they form a unique fingerprint.

  • Cite this

    Parrella, P., Barbano, R., Pasculli, B., Fontana, A., Copetti, M., Valori, V. M., Poeta, M. L., Perrone, G., Righi, D., Castelvetere, M., Coco, M., Balsamo, T., Morritti, M., Pellegrini, F., Onetti-Muda, A., Maiello, E., Murgo, R., & Fazio, V. M. (2014). Evaluation of microRNA-10b prognostic significance in a prospective cohort of breast cancer patients. Molecular Cancer, 13(1), [142]. https://doi.org/10.1186/1476-4598-13-142